<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712283</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579-0628/1</org_study_id>
    <nct_id>NCT00712283</nct_id>
  </id_info>
  <brief_title>Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Group Design Study to Investigate the Effect of 12,5 mg, 25 mg, 50 mg and 75 mg Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      Determination of the ability to drive and operate machines after single and multiple oral
      dose of Neramexane as compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fitness to drive</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychometric test and motor control tests</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane mesylate</intervention_name>
    <description>tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days</description>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers, female and male

          -  age 21 - 50

          -  BMI 18 - 30 kg/m2

          -  experienced drivers with a valid driver's license and at least 3 years of driving
             practice

        Exclusion Criteria:

          -  any clinically relevant finding on physical examination affecting the study objectives

          -  clinically relevant abnormalities in the ECG laboratory values

          -  history or present evidence of clinically relevant metabolic, renal, hepatic,
             pulmonary or cardiovascular disease, CNS disorders, or disturbance of bleeding
             diagnosis of malignancy

          -  females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Merz Pharmaceuticals</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Merz Pharmaceuticals</name_title>
    <organization>Merz Pharmaceuticals GmbH</organization>
  </responsible_party>
  <keyword>fitness to drive</keyword>
  <keyword>operate machines</keyword>
  <keyword>To determine the fitness to drive and operate machines.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

